Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1156-1157

  Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ATHEROSCLEROSIS; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASES; DRUG MECHANISM; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR DEPRESSION; NEOPLASM; NONHUMAN; OBESITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 84991199836     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13117     Document Type: Editorial

References (11)

1. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35–43.
2. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756–758.
3. Waldner M, Fantus D, Solari M, Thomson AW. New perspectives on mTOR inhibitors (Rapamycin, Rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol 2016; 82: 1158–1170.
4. Lutz M, Mielke S. New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease. Br J Clin Pharmacol 2016; 82: 1171–1179.
5. Francipane MG, Lagasse E. Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. Br J Clin Pharmacol 2016; 82: 1180–1188.
6. Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, et al. The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol 2016; 82: 1189–1212.
7. Lee JS, Vo T-T, Fruman DA. Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol 2016; 82: 1213–1228.
8. Evangelisti C, Cenni V, Lattanzi G. Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. Br J Clin Pharmacol 2016; 82: 1229–1244.
9. Maiese K. Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. Br J Clin Pharmacol 2016; 82: 1245–1266.
10. Kurdi A, de Meyer GRY, Martinet W. Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol 2016; 82: 1267–1279.
11. Ignácio ZM, Réus GZ, Arent CO, Abelaira HM, Pitcher MR, Quevedo J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br J Clin Pharmacol 2016; 82: 1280–1290.